Aadi Bioscience Inc (AADI)
7.03
-0.08
(-1.13%)
USD |
NASDAQ |
Mar 31, 09:45
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 171.79M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -58.85% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 10.40 |
| Price to Book Value | 1.085 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 93.19% |
News
Headline
Wire
Time (ET)
MT Newswires
03/29 07:22
PR Newswire
03/28 08:00
Yahoo
03/26 14:00
PR Newswire
03/15 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/12/2023* | -- | Results | Q1 2023 | -- | -0.70 | -- | |
| 05/12/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 03/28/2023 | -- | Results | Q4 2022 | -- | -0.73 | -- | |
| 03/28/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/09/2022 | -- | Results | Q3 2022 | -0.68 | -0.75 | 9.63% | |
| 08/10/2022 | -- | Results | Q2 2022 | -0.69 | -0.73 | 4.99% | |
| 08/10/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/12/2022 | -- | Results | Q1 2022 | -0.66 | -0.68 | 3.41% |
*Estimated Date/Time
Earnings
Profile
| Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States. |
| URL | https://www.aadibio.com |
| Investor Relations URL | https://ir.aadibio.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 12, 2023 (est.) |
| Last Earnings Release | Mar. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 30, 2023.
Fundamentals
| Revenue (TTM) | 15.22M |
| Total Expenses (TTM) | 74.17M |
| Net Income (TTM) | -60.51M |
| Total Assets (Quarterly) | 184.24M |
| Total Liabilities (Quarterly) | 25.86M |
| Shareholders Equity (Quarterly) | 158.38M |
| Cash from Operations (TTM) | -49.64M |
| Cash from Investing (TTM) | -132.89M |
| Cash from Financing (TTM) | 72.62M |
Ratings
Profile
| Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States. |
| URL | https://www.aadibio.com |
| Investor Relations URL | https://ir.aadibio.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 12, 2023 (est.) |
| Last Earnings Release | Mar. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| AADI Tweets |